	US 11,701,386 B2
	Cell
Martin Pulé, London (GB); Shaun Cordoba, London (GB); Simon Thomas, London (GB); Shimobi Onuoha, London (GB); and Matteo Righi, London (GB)
Assigned to AUTOLUS LIMITED, London (GB)
Appl. No. 16/646,906
Filed by AUTOLUS LIMITED, London (GB)
PCT Filed Sep. 12, 2018, PCT No. PCT/GB2018/052583 § 371(c)(1), (2) Date Mar. 12, 2020, PCT Pub. No. WO2019/053420, PCT Pub. Date Mar. 21, 2019.
Claims priority of application No. 1714718 (GB), filed on Sep. 13, 2017.
Prior Publication US 2020/0297766 A1, Sep. 24, 2020
Int. Cl. C12N 15/62 (2006.01); A61K 35/17 (2015.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01)

CPC A61K 35/17 (2013.01) [C07K 14/4705 (2013.01); C07K 14/705 (2013.01); C12N 15/62 (2013.01); C07K 2319/02 (2013.01); C07K 2319/20 (2013.01); C07K 2319/50 (2013.01); C07K 2319/70 (2013.01)]

7 Claims

1. An engineered cell which comprises a CAR and a constitutively active Signal Transducer and Activator of Transcription (STAT) molecule,

wherein the constitutively active STAT molecule is

(a) a dimerized and constitutively active STAT molecule comprising a first STAT polypeptide having a first dimerization domain and a second STAT polypeptide having a second dimerization domain which second dimerization domain specifically binds the first dimerization domain and wherein the dimerization of the first and second STAT polypeptides structurally changes the STAT molecule to a constitutively active form,

(b) a constitutively active STAT molecule comprising a first STAT polypeptide linked to a second STAT polypeptide by a linker sequence, or